National Health Investors is rated a buy, driven by robust macro demand for senior care, portfolio expansion, and a compelling 5% dividend yield. NHI demonstrates strong top-line growth, geographic diversity, and resilient 5-year revenue trends, with recent acquisitions further solidifying its market presence. Despite modest FFO growth expectations and technical bearishness, NHI benefits from an investment-grade Fitch rating, prudent leverage, and strong ROE among peers.